The Association of Visfatin Levels With Metabolic Parameters and Inflammation In Diabetic Nephropathy

To investigate the visfatin levels at the stages of diabetic nephropathy(DNP), changes in visfatin levels according to stages of DNP, and the association of visfatin levels with other anti-inflammatory parameters including high sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6), and tumor necrosis factor alpha(TNFα). Patients were divided into 4 groups based on the glomerular filtration rate (GFR) and albuminuria as follows; Group I: albuminuria60ml/min, Group II:albuminuria 30 to 300 mg per day and GFR>60ml/min, Group III:albuminuria>300mg per day and GFR>60ml/min, and Group IV:albuminuria>300 mg per day and GFR

PDF

___

Writing Group for the SfDiYSG, Dabelea D, Bell RA, et al. Incidence of diabetes in youth in the United States. JAMA 2007; 297: 2716-2724. 2007/06/28. DOI: 10.1001/jama.297.24.2716.

Stumvoll M, Goldstein BJ and van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005; 365: 1333-1346. 2005/04/13. DOI: 10.1016/S0140-6736(05)61032-X.

Kahn CR. Banting Lecture. Insulin action, diabetogenes, and the cause of type II diabetes. Diabetes 1994; 43: 1066-1084. 1994/08/01. DOI: 10.2337/diab.43.8.1066.

Zou C and Shao J. Role of adipocytokines in obesity-associated insulin resistance. J Nutr Biochem 2008; 19: 277-286. 2007/12/07. DOI: 10.1016/j.jnutbio.2007.06.006.

Chen XD, Lei T, Xia T, et al. Increased expression of resistin and tumour necrosis factor-alpha in pig adipose tissue as well as effect of feeding treatment on resistin and cAMP pathway. Diabetes Obes Metab 2004; 6: 271-279. 2004/06/03. DOI: 10.1111/j.1462-8902.2004.0346.x.

Wisse BE, Ogimoto K, Morton GJ, et al. Physiological regulation of hypothalamic IL-1beta gene expression by leptin and glucocorticoids: implications for energy homeostasis. Am J Physiol Endocrinol Metab 2004; 287: E1107-1113. 2004/08/12. DOI: 10.1152/ajpendo.00038.2004.

Rasouli N and Kern PA. Adipocytokines and the metabolic complications of obesity. J Clin Endocrinol Metab 2008; 93: S64-73. 2008/12/04. DOI: 10.1210/jc.2008-1613.

Prieto-Hontoria PL, Perez-Matute P, Fernandez-Galilea M, et al. Role of obesity-associated dysfunctional adipose tissue in cancer: a molecular nutrition approach. Biochim Biophys Acta 2011; 1807: 664-678. 2010/11/30. DOI: 10.1016/j.bbabio.2010.11.004.

Derosa G, Catena G, Gaudio G, et al. Adipose tissue dysfunction and metabolic disorders: Is it possible to predict who will develop type 2 diabetes mellitus? Role of markErs in the progreSsion of dIabeteS in obese paTIeNts (The RESISTIN trial). Cytokine 2019; 127: 154947. 2019/12/08. DOI: 10.1016/j.cyto.2019.154947.

Chen G, Huang W, Hong S, et al. Effectiveness of antiplatelet drugs for the prevention of diabetic nephropathy: A meta-analysis of randomized controlled trials. Clin Nephrol 2018; 90: 419-426. 2018/11/01. DOI: 10.5414/CN109588.

Rheinberger M and Boger CA. [Diabetic nephropathy: new insights into diagnosis, prevention and treatment]. Dtsch Med Wochenschr 2014; 139: 704-706. 2014/03/29. DOI: 10.1055/s-0034-1369841.

Gross JL, de Azevedo MJ, Silveiro SP, et al. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 2005; 28: 164-176. 2004/12/24. DOI: 10.2337/diacare.28.1.164.

Revollo JR, Korner A, Mills KF, et al. Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab 2007; 6: 363-375. 2007/11/07. DOI: 10.1016/j.cmet.2007.09.003.

Yang H, Yang T, Baur JA, et al. Nutrient-sensitive mitochondrial NAD+ levels dictate cell survival. Cell 2007; 130: 1095-1107. 2007/09/25. DOI: 10.1016/j.cell.2007.07.035.

Yilmaz MI, Saglam M, Carrero JJ, et al. Serum visfatin concentration and endothelial dysfunction in chronic kidney disease. Nephrol Dial Transplant 2008; 23: 959-965. 2007/11/07. DOI: 10.1093/ndt/gfm727.

Kocelak P, Olszanecka-Glinianowicz M, Owczarek A, et al. Plasma visfatin/nicotinamide phosphoribosyltransferase (visfatin/NAMPT) concentration is not related to kidney function in elderly subjects. Clin Chem Lab Med 2015; 53: 793-799. 2014/10/03. DOI: 10.1515/cclm-2014-0574.

Mahmood N, Junejo AM, Jamal Q, et al. Association of visfatin with chronic kidney disease in a cohort of patients with and without diabetes. J Pak Med Assoc 2010; 60: 922-926. 2011/03/08.

Axelsson J, Witasp A, Carrero JJ, et al. Circulating levels of visfatin/pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD. Am J Kidney Dis 2007; 49: 237-244. 2007/01/31. DOI: 10.1053/j.ajkd.2006.11.021.

Yilmaz MI, Saglam M, Qureshi AR, et al. Endothelial dysfunction in type-2 diabetics with early diabetic nephropathy is associated with low circulating adiponectin. Nephrol Dial Transplant 2008; 23: 1621-1627. 2008/01/08. DOI: 10.1093/ndt/gfm828.

Kang YS, Song HK, Lee MH, et al. Plasma concentration of visfatin is a new surrogate marker of systemic inflammation in type 2 diabetic patients. Diabetes Res Clin Pract 2010; 89: 141-149. 2010/04/23. DOI: 10.1016/j.diabres.2010.03.020.

Haider DG, Schindler K, Schaller G, et al. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab 2006; 91: 1578-1581. 2006/02/02. DOI: 10.1210/jc.2005-2248.

Taskesen D, Kirel B and Us T. Serum visfatin levels, adiposity and glucose metabolism in obese adolescents. J Clin Res Pediatr Endocrinol 2012; 4: 76-81. 2012/06/08. DOI: 10.4274/jcrpe.547.

Mercader J, Granados N, Caimari A, et al. Retinol-binding protein 4 and nicotinamide phosphoribosyltransferase/visfatin in rat obesity models. Horm Metab Res 2008; 40: 467-472. 2008/04/11. DOI: 10.1055/s-2008-1065324.

Lopez-Bermejo A, Chico-Julia B, Fernandez-Balsells M, et al. Serum visfatin increases with progressive beta-cell deterioration. Diabetes 2006; 55: 2871-2875. 2006/09/28. DOI: 10.2337/db06-0259.

Toruner F, Altinova AE, Bukan N, et al. Plasma visfatin concentrations in subjects with type 1 diabetes mellitus. Horm Res 2009; 72: 33-37. 2009/07/03. DOI: 10.1159/000224338.

Moschen AR, Kaser A, Enrich B, et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007; 178: 1748-1758. 2007/01/24. DOI: 10.4049/jimmunol.178.3.1748.